<DOC>
	<DOCNO>NCT00149396</DOCNO>
	<brief_summary>This study open-label study . It two stage . Stage 1 dose escalation phase study determine evaluate safety tolerability repeat treatment genetically engineer herpes simplex virus NV1020 administer locoregionally liver . Stage 2 evaluate dose find Stage 1 `` optimally tolerate '' . Stage 2 assess efficacy optimally tolerate dose NV1020 combination second-line chemotherapy . Assignment Stage 1 Stage 2 study determine patient enters study .</brief_summary>
	<brief_title>Safety Efficacy Genetically Engineered Herpes Simplex Virus NV1020 Treat Colorectal Cancer Metastatic Liver</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<criteria>1 . Ability understand willingness sign write informed consent ( include willingness avoid physical intimacy 2 week post NV1020 treatment ) 2 . 18 year age 3 . Colorectal adenocarcinoma histologically confirm within one year prior enrollment study 4 . Liver dominant metastasis ( CTmeasurable lesion less 50 % total liver involvement ) , histologically confirm 5 . Failed conventional chemotherapy metastatic disease 6 . Candidate additional chemotherapy 7 . Karnofsky Performance Status 70 % great 8 . Life expectancy great equal 4 month , base investigator 's opinion 9 . Seropositive herpes simplex virus1 ( HSV1 ) 10 . Fecund female : negative pregnancy test ( urine serum ) 11 . Effective doublebarrier contraception minimum 2 month follow final infusion NV1020 1 . Dominant extrahepatic disease , include cerebral metastasis , significant malignant ascites extrahepatic metastasis symptomatic , critical location otherwise likely confound NV1020 evaluation , opinion investigator 2 . Seronegative HSV1 3 . Significant active/unstable nonmalignant disease laboratory test ( hematology chemistry ) result meet following : White blood cell count ( WBC ) less equal 3 x 10e3/mm3 Absolute neutrophil count ( ANC ) less equal 1.5 x 10e3/mm3 Platelets less equal 100,000/mm3 Hemoglobin ( Hgb ) less equal 9.0 g/dL Prothrombin time/partial thromboplastin time ( PT/PTT ) &gt; upper limit normal ( ULN ) Serum creatinine &gt; 2.0 mg/dL AST ALT &gt; 2.5 time ULN total bilirubin &gt; 1.5 time ULN Alkaline phosphatase &gt; 2.5 time ULN 4 . Chemotherapy &lt; 4 week prior first NV1020 infusion ( mitomycin nitrosurea &lt; 6 week ) 5 . Immunotherapy &lt; 6 week prior first NV1020 infusion 6 . Radiotherapy ( external internal ) liver 7 . Major surgery ( exclude pump placement cholecystectomy ) less equal 2 week prior first NV1020 infusion patient must clinically stable . Pump placement cholecystectomy less equal 1 week prior first NV1020 infusion 8 . Female pregnant nursing 9 . Patients wish conceive within 2 month last infusion NV1020 10 . Any investigational agent administer less equal 4 week prior NV1020 infusion 11 . Acute HSV infection require systemic antiviral therapy history serious HSV infection ( e.g. , ocular , encephalitic , etc . ) 12 . Active viral hepatitis ( evidence infection hepatitis A , B C virus ) 13 . Known infection HIV 14 . Known hypersensitivity component NV1020 formulation 15 . History , current , bleed coagulation disorder 16 . History significant hepatic fibrosis , cirrhosis , hemachromatosis 17 . History malignancy colorectal cancer , within 5 year prior start study participation , exception situ cervical skin carcinoma 18 . Active severe infection concurrent disease medical condition likely interfere study , judge investigator 19 . Systemic corticosteroid administration &lt; 4 week prior start NV1020 treatment 20 . Prior treatment NV1020 putative oncolytic virus</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>Colorectal cancer metastasis liver</keyword>
	<keyword>Colorectal Cancer</keyword>
	<keyword>Colorectal Carcinoma</keyword>
	<keyword>Colorectal Tumors</keyword>
	<keyword>Colorectal Neoplasms</keyword>
	<keyword>Rectum Cancer</keyword>
	<keyword>Rectum tumor</keyword>
	<keyword>Rectum carcinoma</keyword>
	<keyword>Colon cancer</keyword>
	<keyword>Colon tumor</keyword>
	<keyword>Colon carcinoma</keyword>
	<keyword>Rectum Neoplasms</keyword>
	<keyword>Colon Neoplasms</keyword>
	<keyword>Liver Neoplasms</keyword>
	<keyword>Hepatic Neoplasms</keyword>
	<keyword>Liver Tumors</keyword>
	<keyword>Liver cancer</keyword>
	<keyword>Hepatic Cancer</keyword>
	<keyword>Hepatic tumor</keyword>
	<keyword>metastatic liver</keyword>
</DOC>